NRI industrialist Lord Swraj Paul announced today that he has agreed arrangements with the University of Wolverhampton to invest in a spin-out company that is developing a new anti-cancer drug.
The new company, Disulfican Ltd, has been formed to build on research carried out by Prof Weiguang Wang, Professor of Experimental Cancer Therapeutics at the University of Wolverhampton. It will receive an investment of around 200,000 pounds from the varsity and the Caparo Angad Paul Fund, set by Paul in memory of his late son Angad.
Led by Wang, the Cancer Research Group (CRG) is developing a treatment based on Disulfican an existing drug used to treat alcoholism - which had showed promising results in pre-clinical testing as a new anti-cancer therapy.
Initial research was conducted by the CRG within the Faculty of Science and Engineering at the University of Wolverhampton, where Lord Paul is the Chancellor.
